Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering ...

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Evaluating the impact of the Inflation Reduction Act (IRA) will require real-time data and effective therapy metrics, ...

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...